Yitzhak Peterburg - Rosetta Genomics Director
Director
Dr. Yitzhak Peterburg serves as a director of the company, since December 2012. Dr. Peterburg has also served as a consultant to Rosetta since October 2012. He currently serves on the Board of Directors of TEVA Pharmaceuticals, prior to which he served as TEVAs Senior Vice President, Head of Global Branded Products, prior to which he served on the board of TEVA. Prior to his positions with TEVA, Dr. Peterburg was President and CEO of Cellcom, one of Israel leading cellular companies. Between the years of 1990 to 2002, Dr. Peterburg was with Clalit Health Services, a nongovernmental, notforprofit organization that provides comprehensive health services to more than 55 percent of the Israeli population. From 1997 to 2002 he served as General Manager for Clalit Health Services and from 1990 to 1997 he held a series of senior executive positions including Head, Health Policy Division and Chief Information Officer, Medical Division. Among his many positions at Clalit, from 19951997, Dr. Peterburg served as CEO of Soroka University Medical Center, BeerSheba, Israel, one of the biggest university hospitals in Israel since 2012.
Age | 65 |
Tenure | 12 years |
Phone | 972 73 222 0700 |
Web | http://www.rosettagx.com |
Rosetta Genomics Management Efficiency
The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (137.95) %, meaning that it created substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rosetta Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Rosetta Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rosetta Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rosetta to invest in growth at high rates of return. When we think about Rosetta Genomics' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Susan Ellerbusch | Summit Materials | 53 | |
Richard Beyer | Analog Devices | 66 | |
William Strauss | ServiceNow | 56 | |
Kenton Sicchitano | Analog Devices | 73 | |
Ian McWalter | Evertz Technologies Limited | 58 | |
Neil Novich | Analog Devices | 63 | |
Karen Golz | Analog Devices | 63 | |
Anne Cooney | Summit Materials | 61 | |
Adrian Pertierra | Asure Software | 45 | |
Thomas Pistor | Evertz Technologies Limited | N/A | |
Yves Istel | Analog Devices | 79 | |
Ronald Codd | ServiceNow | 61 | |
Charles Lathrop | Asure Software | 61 | |
Paul Chamberlain | ServiceNow | 56 | |
Edward Frank | Analog Devices | 61 | |
John Hodgson | Analog Devices | 71 | |
Christopher Colclough | Evertz Technologies Limited | N/A | |
Charles Giancarlo | ServiceNow | 58 | |
Anita Sands | ServiceNow | 43 | |
Julia Kahr | Summit Materials | 37 | |
Dennis Woodside | ServiceNow | 51 |
Management Performance
Return On Equity | -137.95 | |||
Return On Asset | -60.19 |
Rosetta Genomics Leadership Team
Elected by the shareholders, the Rosetta Genomics' board of directors comprises two types of representatives: Rosetta Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rosetta. The board's role is to monitor Rosetta Genomics' management team and ensure that shareholders' interests are well served. Rosetta Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rosetta Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Sidransky, Independent Director | ||
Kenneth Berlin, CEO and Pres | ||
Anne Fields, IR Contact Officer | ||
Joshua Rosensweig, Director | ||
Dganit Bar, Chief Scientific Officer | ||
Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee | ||
Douglas Sites, Executive Vice President - Sales and Marketing | ||
Tal YaronEldar, Independent Director | ||
Eti Meiri, Vice President - Research | ||
Robert Wassman, Chief Medical Officer | ||
Oded Biran, General Counsel | ||
Roy Davis, Director | ||
Yitzhak Peterburg, Director | ||
Kevin Watson, Director, Reimbursement-Managed Care | ||
Ron Kalfus, CFO | ||
Gerald Dogon, External Independent Director | ||
Tali YaronEldar, External Independent Director |
Rosetta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rosetta Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -137.95 | |||
Return On Asset | -60.19 | |||
Operating Margin | (370.55) % | |||
Current Valuation | 2.09 M | |||
Shares Outstanding | 5.93 M | |||
Shares Owned By Insiders | 0.20 % | |||
Shares Owned By Institutions | 14.42 % | |||
Number Of Shares Shorted | 310.26 K | |||
Price To Earning | (0.09) X | |||
Price To Book | 1.01 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Rosetta Stock
If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |